Castrejon et al. Cancer risk with b/tsDMARD in BIOBADASER. Again not looking great for abatacept, Rate ratio vs TNFi 2.2 (1.4-3.2). Age-adjusted HR 1.6 (1.0-2.6) @RheumNow #ACR22 Abstr#1752 https://t.co/PvBq2O9qPv https://t.co/XBfistBMhW
Links:
Cancer Risk in Patients with Rheumatic Diseases Exposed to Different Biologic a…
https://acrabstracts.org/abstract/cancer-risk-in-patients-with-rheumatic-diseas…
14-11-2022